Background: Patients with kidney failure on dialysis or after renal transplantation have a high risk for severe COVID-19 infection, and vaccination against SARS-CoV-2 is the only expedient prophylaxis. Generally, immune responses are attenuated in patients with kidney failure, however, systematic analyses of immune responses to SARS-CoV-2 vaccination in patients on dialysis and in kidney transplant recipients (KTRs) are still needed. Methods: In this prospective, multicentric cohort study, antibody responses to COVID-19 mRNA vaccines (BNT162b2 [BioNTech/Pfizer] or mRNA-1273 [Moderna]) were measured in 32 patients on dialysis and in 28 KTRs. SARS-CoV-2-specific antibodies and neutralization capacity were evaluated and compared with controls (n=78) of a similar age range. Results: After the first vaccination, SARS-CoV-2-specific antibodies were nearly undetectable in patients with kidney failure. After the second vaccination, 93% of the controls and 88% of patients on dialysis but only 37% of KTRs developed SARS-CoV-2-specific IgG above cutoff. Moreover, mean IgG levels were significantly lower in KTRs (54±93 BAU/ml) compared with patients on dialysis (503±481 BAU/ml; P<0.01). Both KTRs and patients on dialysis had significantly lower IgG levels compared with controls (1992±2485 BAU/ml; P<0.001 and P<0.01, respectively). Importantly, compared with controls, neutralizing antibody titers were significantly lower in KTRs and patients on dialysis. After the second vaccination, 76% of KTRs did not show any neutralization capacity against SARS-CoV-2, suggesting impaired seroprotection. Conclusions: Patients with kidney failure show a significantly weaker antibody response compared with controls. Most strikingly, only one out of four KTRs developed neutralizing antibodies against SARS-CoV-2 after two doses of vaccine. These data suggest that vaccination strategies need modification in KTRs and patients on dialysis.Clinical Trial registry name and registration number: Vaccination Against COVID-19 in Chronic Kidney Disease, NCT04743947.
Background: Patients with kidney failure on dialysis or after renal transplantation have a high risk for severe COVID-19 infection, and vaccination against SARS-CoV-2 is the only expedient prophylaxis. Generally, immune responses are attenuated in patients with kidney failure, however, systematic analyses of immune responses to SARS-CoV-2 vaccination in patients on dialysis and in kidney transplant recipients (KTRs) are still needed. Methods: In this prospective, multicentric cohort study, antibody responses to COVID-19 mRNA vaccines (BNT162b2 [BioNTech/Pfizer] or mRNA-1273 [Moderna]) were measured in 32 patients on dialysis and in 28 KTRs. SARS-CoV-2-specific antibodies and neutralization capacity were evaluated and compared with controls (n=78) of a similar age range. Results: After the first vaccination, SARS-CoV-2-specific antibodies were nearly undetectable in patients with kidney failure. After the second vaccination, 93% of the controls and 88% of patients on dialysis but only 37% of KTRs developed SARS-CoV-2-specific IgG above cutoff. Moreover, mean IgG levels were significantly lower in KTRs (54±93 BAU/ml) compared with patients on dialysis (503±481 BAU/ml; P<0.01). Both KTRs and patients on dialysis had significantly lower IgG levels compared with controls (1992±2485 BAU/ml; P<0.001 and P<0.01, respectively). Importantly, compared with controls, neutralizing antibody titers were significantly lower in KTRs and patients on dialysis. After the second vaccination, 76% of KTRs did not show any neutralization capacity against SARS-CoV-2, suggesting impaired seroprotection. Conclusions: Patients with kidney failure show a significantly weaker antibody response compared with controls. Most strikingly, only one out of four KTRs developed neutralizing antibodies against SARS-CoV-2 after two doses of vaccine. These data suggest that vaccination strategies need modification in KTRs and patients on dialysis.Clinical Trial registry name and registration number: Vaccination Against COVID-19 in Chronic Kidney Disease, NCT04743947.
Authors: Brian J Boyarsky; William A Werbel; Robin K Avery; Aaron A R Tobian; Allan B Massie; Dorry L Segev; Jacqueline M Garonzik-Wang Journal: JAMA Date: 2021-06-01 Impact factor: 56.272
Authors: Andrew Clark; Mark Jit; Charlotte Warren-Gash; Bruce Guthrie; Harry H X Wang; Stewart W Mercer; Colin Sanderson; Martin McKee; Christopher Troeger; Kanyin L Ong; Francesco Checchi; Pablo Perel; Sarah Joseph; Hamish P Gibbs; Amitava Banerjee; Rosalind M Eggo Journal: Lancet Glob Health Date: 2020-06-15 Impact factor: 26.763
Authors: Dorey A Glenn; Anisha Hegde; Elizabeth Kotzen; Emmanuel B Walter; Abhijit V Kshirsagar; Ronald Falk; Amy Mottl Journal: Kidney Int Rep Date: 2021-02-09
Authors: Eleftheria Vasileiou; Colin R Simpson; Ting Shi; Steven Kerr; Utkarsh Agrawal; Ashley Akbari; Stuart Bedston; Jillian Beggs; Declan Bradley; Antony Chuter; Simon de Lusignan; Annemarie B Docherty; David Ford; Fd Richard Hobbs; Mark Joy; Srinivasa Vittal Katikireddi; James Marple; Colin McCowan; Dylan McGagh; Jim McMenamin; Emily Moore; Josephine Lk Murray; Jiafeng Pan; Lewis Ritchie; Syed Ahmar Shah; Sarah Stock; Fatemeh Torabi; Ruby Sm Tsang; Rachael Wood; Mark Woolhouse; Chris Robertson; Aziz Sheikh Journal: Lancet Date: 2021-04-23 Impact factor: 202.731
Authors: Noa Dagan; Noam Barda; Eldad Kepten; Oren Miron; Shay Perchik; Mark A Katz; Miguel A Hernán; Marc Lipsitch; Ben Reis; Ran D Balicer Journal: N Engl J Med Date: 2021-02-24 Impact factor: 91.245
Authors: Marta Kantauskaite; Lisa Müller; Thilo Kolb; Svenja Fischer; Jonas Hillebrandt; Katrin Ivens; Marcel Andree; Tom Luedde; Hans M Orth; Ortwin Adams; Heiner Schaal; Claudia Schmidt; Eva Königshausen; Lars C Rump; Jörg Timm; Johannes Stegbauer Journal: Am J Transplant Date: 2021-11-01 Impact factor: 9.369
Authors: Amanda J Vinson; Alfred J Anzalone; Jing Sun; Ran Dai; Gaurav Agarwal; Stephen B Lee; Evan French; Amy Olex; Michael G Ison; Roslyn B Mannon Journal: Am J Transplant Date: 2022-06-20 Impact factor: 9.369
Authors: Marta Kantauskaite; Lisa Müller; Jonas Hillebrandt; Joshua Lamberti; Svenja Fischer; Thilo Kolb; Katrin Ivens; Michael Koch; Marcel Andree; Nadine Lübke; Michael Schmitz; Tom Luedde; Hans Martin Orth; Torsten Feldt; Heiner Schaal; Ortwin Adams; Claudia Schmidt; Margarethe Kittel; Eva Königshausen; Lars C Rump; Jörg Timm; Johannes Stegbauer Journal: Clin Transplant Date: 2022-08-23 Impact factor: 3.456